Medtronic launches atrial fibrillation trial; Investor sues NuVasive for unpaid milestone money;

 @FierceMedDev: FDA plans to clamp down on all-metal hips. Article | Follow @FierceMedDev

 @DamianFierce: Big M&A morning: Stryker's ($SYK) spending $764 million on Chinese orthopedics company Trauson. Release | Follow @DamianFierce

> Medtronic ($MDT) has launched a trial to see whether its Reveal Insertable Cardiac Monitor can identify and predict atrial fibrillation in patients at high risk for the disease. More

> Gore is launching a new version of its Q50 Plus Stent Graft Balloon Catheter, a device made to work with aortic stent grafts and treat abdominal aortic aneurysms. Release

> Devicemaker Sanovas has filed for FDA clearance for its Vas Zeppelin Smart Catheter, designed to treat chronic pulmonary diseases and lung cancer. News

> Back in 2009, when NuVasive ($NUVA) acquired Cervitech, it agreed to pay out milestones when the company's device got FDA approval. Now, a Cervitech investor is suing, saying he never got his cut. Story

> Drug delivery specialist pSivida ($PSDV) is expanding the use of its back-of-the-eye delivery device, as Iluvien, a drug that uses the tech, got market approval in Spain. Item

> Covidien ($COV) is partnering with the NFL Players Association and the Living Heart Foundation to launch the HOPE Program, designed to promote healthy lifestyles for former NFL athletes. Release

Biotech News

 @FierceBiotech: Popular yesterday : Buzz: $AZN reorg inspires fresh rumors of $SHPG bid. Report | Follow @FierceBiotech

@JohnCFierce: Columnist gushes over Inovio's Kim, a tireless promoter whose stock is trading at .67 and whose flu vax is in PhI. Column | Follow @JohnCFierce

@RyanMFierce: $EXEL's plethora of partnerships bearing fruit as Genentech moves melanoma drug from EXEL into PhIII. More | Follow @RyanMFierce

> FDA green-lights a flu vaccine made with new technology. Story

> Genentech launches PhIII for melanoma combo with GSK in hot pursuit. Article

> AstraZeneca shakeup pushes research chief to top of restructured MedImmune. News

Pharma News

@FiercePharma: Bond market pants for Pfizer vet unit's debut offering: Zoetis sets up $3.65B in debt amid final prep for IPO. More | Follow @FiercePharma

 @AlisonBFierce: FierceVaccines brings you the major FDA vaccine approvals from 2012. Special Report | Follow @AlisonBFierce

> Aranesp flunks heart-failure trial, raising new questions about use. News

> MedImmune unit split 3 ways in AstraZeneca shake-up. More

> AARP, AFL-CIO and prominent docs to White House: Get us the sunshine rules, stat. Story

Vaccines News

> IOM confirms safety of childhood vaccine schedule. Report

> CDC: Flu hits epidemic level in U.S. Item

> Protein Sciences nabs Flublok approval. News

> Vaccine stakes upped as dengue dubbed fastest-spreading tropical disease. Article

> Flu vaccine, Tamiflu shortage as influenza sweeps U.S. Story

Pharma Manufacturing News

 @EricPFierce: Amgen to build $200 million monoclonal antibody plant in Singapore. Novartis building there too. More | Follow @EricPFierce

> Wisconsin report adds to drug take-back funding debate. Item

> China ups bounty for tips on counterfeiters to $48,500. Report

> Japan's Mitsui ups stake in India API maker Arch. Story

> FDA spells out user fees for generic drugs. Article

> J&J consent decree cost felt at the pharmacy. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.